Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ASP 5854

Known as: ASP-5854, ASP5854 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Brain Adenosine A2A Receptor Occupancy by a Novel A1/A2A Receptor Antagonist, ASP5854, in Rhesus Monkeys: Relationship to Anticataleptic Effect
The purpose of the present study was to measure adenosine A2A receptor (A2AR) occupancy in the brain by a novel adenosine A1/A2A… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2008
2008
A novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs
Recent evidence indicates that adenosine A(2A) receptor antagonists hold therapeutic potential for the treatment of Parkinson's… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2007
Highly Cited
2007
Pharmacological Characterization of a Novel, Potent Adenosine A1 and A2A Receptor Dual Antagonist, 5-[5-Amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in Models of…
Central adenosine A2A receptor is a promising target for drugs to treat Parkinson's disease (PD), and the central blockade of… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE